158 related articles for article (PubMed ID: 37788147)
1. Treatment of primary cancer in metastatic hormone-sensitive prostate cancer.
Lim KY; Alberto M; Ranasinghe W
Curr Opin Support Palliat Care; 2023 Dec; 17(4):315-323. PubMed ID: 37788147
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
Rajwa P; Zattoni F; Maggi M; Marra G; Kroyer P; Shariat SF; Briganti A; Montorsi F; Heidegger I; Gandaglia G;
Eur Urol Focus; 2023 Jul; 9(4):637-641. PubMed ID: 36697321
[TBL] [Abstract][Full Text] [Related]
3. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
4. Role of radical prostatectomy in metastatic prostate cancer: A review.
Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
[TBL] [Abstract][Full Text] [Related]
5. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
Buelens S; Poelaert F; Claeys T; De Bleser E; Dhondt B; Verla W; Ost P; Rappe B; De Troyer B; Verbaeys C; Kimpe B; Billiet I; Plancke H; Fransis K; Willemen P; Ameye F; Decaestecker K; Lumen N
BJU Int; 2022 Jun; 129(6):699-707. PubMed ID: 34289231
[TBL] [Abstract][Full Text] [Related]
6. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
8. [Primary Tumour Treatment in Patients with Metastatic Prostate Cancer].
Steuber T; Beyer B
Aktuelle Urol; 2016 Sep; 47(5):388-94. PubMed ID: 27680190
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. [Surgical treatment of local disease in metastatic prostate cancer.].
Gaya JM; Huguet J; Breda A; Palou J
Arch Esp Urol; 2018 Mar; 71(3):288-297. PubMed ID: 29633950
[TBL] [Abstract][Full Text] [Related]
11. Metastatic hormone sensitive prostate cancer: local treatment strategies.
Walz J; Pignot G; Fakhfakh S; Campagna J; Guerin M; Vicier C; Brunelle S; Salem N; Gravis G
World J Urol; 2021 Feb; 39(2):327-337. PubMed ID: 32588203
[TBL] [Abstract][Full Text] [Related]
12. Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease.
Heidenreich A; Pfister D
Curr Opin Urol; 2020 Jan; 30(1):90-97. PubMed ID: 31724996
[TBL] [Abstract][Full Text] [Related]
13. Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?
Marenco J; Sooriakumaran P
Arch Esp Urol; 2019 Mar; 72(2):174-181. PubMed ID: 30855019
[TBL] [Abstract][Full Text] [Related]
14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis.
Shemshaki H; Al-Mamari SA; Geelani IA; Kumar S
Urologia; 2022 Feb; 89(1):16-30. PubMed ID: 34355602
[TBL] [Abstract][Full Text] [Related]
17. Treating the primary in metastatic prostate cancer: where do we stand?
Nason GJ; Hamilton RJ
Curr Opin Support Palliat Care; 2019 Sep; 13(3):243-248. PubMed ID: 31082943
[TBL] [Abstract][Full Text] [Related]
18. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
19. Emerging role for local therapy in oligometastatic prostate cancer.
Khondakar NR; Owens-Walton J; Daneshvar M; Williams C; O'Connor L; Yerram NK; Pinto PA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):460-467. PubMed ID: 34236345
[TBL] [Abstract][Full Text] [Related]
20. [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].
Heidenreich A; Pfister D; Porres D
Urologe A; 2014 Jun; 53(6):823-31. PubMed ID: 24824471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
